Short-Course Anti-tuberculosis Regimens for Mild Spinal Tuberculosis

To evaluate the non-inferiority in efficacy between the rifapentine- and moxifloxacin-containing short-course regimens (with rifampicin replaced by rifapentine and ethambutol replaced by moxifloxacin, while isoniazid and pyrazinamide remaining the same as the empirical regimen) and the empirical long-course regimen, so as to determine whether it is possible to shorten the treatment duration to 26 weeks for patients with mild spinal tuberculosis.

NCT Number	NCT06917495
Lead Sponsor	Shandong University Collaborators: Shandong Public Health Clinical Center
Conditions	Mild Spinal Tuberculosis
Enrollment	300 participants
Start Date	2025-04-05
Primary Completion	2027-12-31 (estimated)
Study Completion	2029-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-04-08